Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
323.10+7.13 (+2.26%)
At close: 04:00PM EDT
323.75 +0.65 (+0.20%)
After hours: 05:38PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

    SVB Securities initiated coverage on Argenx SE (NASDAQ: ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart in generalized myasthenia gravis (gMG) following its December 2021 FDA approval. Vyvgart reported over $21

  • GlobeNewswire

    argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

    Translational data from Phase 2 study of efgartigimod in pemphigus further demonstrate argenx’s scientific leadership in FcRn biology, providing new insights into pathophysiology of autoimmune skin blistering diseases and potential role of FcRn blockadeData to be included in symposium presentation at Society for Investigative Dermatology (SID) Annual Meeting being held today, May 19, 2022, 7:30am PT May 19, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co

  • GlobeNewswire

    argenx announces results of Annual General Meeting of Shareholders

    May 10, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that all proposed resolutions at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed. As part of the approved resolutions: The company's annual report and annual accounts for the financial year ending December 31, 2021, were approved;The advisory vote on

Advertisement
Advertisement